Source comparison
BPC-157 TB-500 for Tendon Healing: Protocol Comparison
Primary Mechanism VEGF upregulation, extracellular matrix stabilization, NO pathway activation Actin polymerization, anti-inflammatory cytokine modulation, VEGF expression Dual-pathway targeting: angiogenesis + matrix stabilization (BPC-157) plus migration + a
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF upregulation, extracellular matrix stabilization, NO pathway activation
- Actin polymerization, anti-inflammatory cytokine modulation, VEGF expression
- Dual-pathway targeting: angiogenesis + matrix stabilization (BPC-157) plus migration + anti-fibrosis (TB-500)
- Combined protocols address both structural rebuilding and inflammation resolution
- Typical Dosing
- 250–500 mcg/day subcutaneous near injury site
- Loading: 2–2.5mg twice weekly for 4–6 weeks; Maintenance: 2mg weekly
- BPC-157 daily + TB-500 loading/maintenance schedule as above
- TB-500's longer half-life allows less frequent dosing than BPC-157
- Observable Effect Timeline
- Pain reduction and improved range of motion within 7–14 days in partial tears
- Reduced stiffness and improved tissue pliability within 14–21 days
- Faster inflammation resolution (week 1–2) and earlier load tolerance (week 3–4) than either alone
- Combined use shortens each phase of the healing cascade
- Evidence Base
- Multiple rodent tendon injury studies (2011–2022); no Phase 3 human trials
- Rodent and equine studies; one small human pilot (n=16) for muscle injury
- No published combined-use trials; evidence is extrapolated from separate studies
- All human efficacy claims are based on animal data and anecdotal case series
- Cost per 4-Week Cycle
- ~$60–80 for research-grade BPC-157 at 500 mcg/day
- ~$120–150 for research-grade TB-500 loading phase
- ~$180–230 combined
- Combined protocols double the cost but target mechanistically distinct pathways